Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 3933)

LOAN FACILITY WITH BANK OF COMMUNICATIONS HONG KONG - ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Company, as borrower, has entered into the Facility Letter with Bank of Communications (Hong Kong) Limited for a term loan facility of HK\$300,000,000.

The Facility Letter imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board of directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") announces that the Company, as borrower, has entered into a facility letter (the "Facility Letter") with Bank of Communications (Hong Kong) Limited for a term loan facility of HK\$300,000,000. The term loan facility shall be available for 12 months from the date of acceptance of the Facility Letter. The term loans under the facility shall be repaid by instalments as 10%, 20%, 20% and 50% of all loans outstanding in the 18, 24, 30 and 36 months respectively from the date of first drawdown.

The Facility Letter imposes, among other matters, Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit, Ms. Ning Kwai Chun and their family trusts shall (i) individually or collectively have the largest shareholding interest in the Company and beneficially own in aggregate (directly or indirectly) at least 40% of beneficial interest, and carrying at least 40% of the voting rights, in all issued share capital of the Company; (ii) be the chairman of the Board; and (iii) remain the absolute management control over the Company and its group.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board The United Laboratories International Holdings Limited Tsoi Hoi Shan Chairman

Hong Kong, 13 December 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.